首页> 外文期刊>応用薬理 >Hydrophilia, Tablet Strength, and Pushing Out by Pressing Through the Package of Acarbose and Rebamipide Orally Disintegrating Tablets
【24h】

Hydrophilia, Tablet Strength, and Pushing Out by Pressing Through the Package of Acarbose and Rebamipide Orally Disintegrating Tablets

机译:疏水性,片剂强度,并通过压制氨基糖和重生口口腔崩解片来推出

获取原文
获取原文并翻译 | 示例
           

摘要

Here we used a brand-name and two generic acarbose orally disintegrating (OD) tablets and three generic rebamipide OD tablets (formulations A, B, and C in both groups) and examined hydrophilia, tablet strength, and pushing out by press through package (PTP) to evaluate the quality of each formulation. In the case of acarbose OD tablets, the wetting time of formulation C (52 ± 4 sec) was approximately 1.6 fold of those of formulations A and B (31 ± 1 sec and 32 ± 3 sec, respectively) and PTP pushing out strength of formulation C (46.3 ± 1.6 N) was approximately 1.5-1.9 fold of those of formulations A and B (24.5 ± 1.6 N and 30.0 ± 1.3 N, respectively). In the case of rebamipide OD tablets, no major differences in wetting time and PTP pushing out strength between formulations A, B, and C were observed. In both acarbose and rebamipide OD tablets, each formulation had hardness ( >3 kgf) and friability (< 1%) that could endure vibration and impact in the manufacturing process and transporting. These findings indicated that the quality of acarbose OD tablets was different between the formulations in hydrophilia and pushing out by PTP, and the quality of rebamipide OD tablets was equivalent between formulations. This study provides useful information for selecting acarbose and rebamipide OD tablets suitable for the individual patient.
机译:在这里,我们使用了一个名牌和两个通用的氨基糖口服崩解(OD)片剂和三种通用肉虫蛋白酶OD片剂(两组配方A,B和C),并检查了患者,片剂强度,并通过通过封装通过压力推出( PTP)以评估每种配方的质量。在Acarbose OD片剂的情况下,制剂C(52±4秒)的润湿时间约为配方A和B(31±1秒和32±3秒)和PTP的强度制剂C(46.3±1.6 n)约为5.5-1.9倍的制剂A和B(分别为24.5±1.6 n和30.0±1.3 n)。在重生外部片剂的情况下,观察到在制剂A,B和C之间的润湿时间和PTP中没有重大差异。在Acarbose和Refamipide OD片剂中,每种配方具有硬度(> 3kgf)和可脆性(<1%),可以忍受制造过程和运输中的振动和影响。这些发现表明,患有嗜睡剂的配方和通过PTP推出的Acarbose OD片剂的质量不同,并且在制剂之间的替​​代品OD片剂的质量相当于。本研究提供了用于选择适用于个体患者的acarbose和rebamipide OD片剂的有用信息。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号